Please login to the form below
Zuranolone
This page shows the latest Zuranolone news and features for those working in and with pharma, biotech and healthcare.
Biogen, Sage’s depression therapeutic zuranolone hits primary endpoint in phase 3
Although this finding was not statistically significant, there was a ‘numerical advantage’ in favour of zuranolone demonstrated at day 42. ... The most common TEAEs in the zuranolone group included somnolence, dizziness, headache and sedation.
Latest news
-
Biogen signs $3.1bn deal with Sage for potential depression therapies
Outside the US, Biogen will hold responsibility for development and commercialisation with respect to zuranolone, excluding Japan, Taiwan and South Korea. ... Zuranolone is currently being studied in phase 3 development and has already picked up a
-
Sage slides off a MOUNTAIN as depression drug flunks trial
The company has just revealed that the pivotal phase 3 MOUNTAIN trial of its drug SAGE-217 – also known as zuranolone – missed its primary endpoint in major depressive disorder (MDD), wiping
More from news
Approximately 3 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Pfizer reports positive results for elranatamab in multiple myeloma
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- Pfizer’s RSV vaccine approved by FDA for older adults
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Janssen shares positive phase 3 results for erdafitinib in bladder cancer
- Generative AI is coming for healthcare
- Merck sues US government over Medicare drug price negotiation programme
- GSK’s RSV vaccine approved by European Commission for older adults
- The 17th World Congress on Controversies in Neurology
No results were found
PMHub
Research Partnership
Research Partnership, an Inizio Advisory Company, is a world-leading custom and syndicated global insights partner for health and life science...
Latest intelligence
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
